Login to Your Account



Clinic Roundup


Wednesday, January 19, 2011
Diamyd Medical AB, of Stockholm, Sweden, dosed the first patient in a Phase II trial of its NP2 Enkephalin candidate aimed at reducing cancer pain. The trial will recruit about 32 subjects with severe cancer pain and will follow their pain scores and concomitant opioid pain medication usage.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription